An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis. The findings suggest – for the first time in a clinical trial – that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer’s dementia.

A recent study conducted by researchers from Arizona State University has uncovered alarming levels of Fusarium mycotoxins in illicit cannabis samples seized in Arizona and California. The study found that 16% of the 118 samples tested positive for harmful mycotoxins, posing potential health risks to consumers. This groundbreaking research highlights the unregulated and dangerous nature of black-market cannabis.